ImmunityBio (IBRX) Announces Preliminary Financial Results for the Quarter Ended June 30

ImmunityBio, Inc. (NASDAQ:IBRX) is one of the best strong buy penny stocks to buy now. On July 25, ImmunityBio, Inc. (NASDAQ:IBRX) announced the preliminary financial results for the fiscal quarter ended June 30.

ImmunityBio (IBRX) Jumps 18% on Anktiva Access Expansion

A technician analyzing natural killer cells, as part of an immune system study and research into therapeutical agents.

The company reported a notable 60% revenue growth to $26.4 million from Q1 2025, with year-to-date sales of ~$43 million. ANKTIVA underwent a 246% unit sales volume growth in H1 2025 compared to H2 2024.

ImmunityBio, Inc. (NASDAQ:IBRX) also reported $153.7 million in cash, cash equivalents, and marketable securities as of June 30.

ImmunityBio, Inc. (NASDAQ:IBRX) is a clinical-stage immunotherapy company that develops next-generation therapies to treat cancer and infectious diseases. Its immunotherapy platform activates the adaptive and innate immune systems to create long-term immunological memory.

While we acknowledge the potential of IBRX to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than IBRX and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.